Directorate Change

RNS Number : 4509S

Genedrive PLC

16 November 2021

 

genedrive plc

("genedrive" or the "Company")

Directorate Change

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Group's Chief Financial Officer has notified the Board of his intention to stand down after five years in the role, in order to take up a position as Chief Financial Officer of musicMagpie plc. 

Matthew Fowler will continue to fulfil the role of Chief Financial Officer for a period of time and his formal departure date will be communicated in due course. In the meantime, the Board will commence the search for a successor.

Ian Gilham, Chairman of genedrive, said; "I would like to thank Matthew for his contribution over the last five years. The Board and I wish him the very best for the future and in his new role."

For further details please contact:

genedrive plc
David Budd: CEO / Matthew Fowler: CFO		[phone]
Peel Hunt LLP (Nominated Adviser and Joint Broker)		[phone]
James Steel
finnCap (Joint Broker)		[phone]
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media Relations & In vestor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy		[phone] / [phone]

About genedrive plc ( http://www.genedriveplc.com ) 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV and certain military biological targets. The Company recently released a high throughput SARS-CoV-2 assay and has a point of care version of the SARS-Cov-2 test due on market during 2021.

 

END

 

 

BOAUVVWRASUAAAA